OR WAIT null SECS
Phesi Inc. announced the creation of a digital twin for Cytokine Release Syndrome (CRS) patients following CAR-T therapy. CAR-T immunotherapies have become widely used in treatment of lymphomas, leukemia, and multiple myeloma; this trend is expected to increase. CRS is one of the most frequent and serious side effects of CAR-T therapy and has only one FDA-approved treatment, Tocilizumab. Phesi created the digital twin for the CRS patient population based on an analysis of 5,473 CAR-T treated patients.
Read more about the digital twin here.